Promising new cocktail of drugs may extend life for kidney cancer patients
NCT ID NCT05899049
First seen Nov 10, 2025 · Last updated Apr 24, 2026 · Updated 15 times
Summary
This study tests whether adding two newer drugs (belzutifan and lenvatinib) to a standard immunotherapy (pembrolizumab) can help Chinese patients with advanced clear cell kidney cancer live longer and keep their cancer from growing. About 249 participants will receive one of three drug combinations. The goal is to see if the new combos work better than the current standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, RENAL CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer hospital-Renal carcinoma and melanoma ( Site 6000)
Beijing, Beijing Municipality, 100142, China
-
Chongqing University Cancer Hospital ( Site 6009)
Chongqing, Chongqing Municipality, 400030, China
-
Guangzhou First People's Hospital ( Site 6007)
Guangzhou, Guangdong, 510180, China
-
Henan Cancer Hospital-Urology ( Site 6006)
Zhengzhou, Henan, 450008, China
-
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( S
Nanjing, Jiangsu, 210000, China
-
Ningbo First Hospital-Urology ( Site 6028)
Ningbo, Zhejiang, 315010, China
-
SUN YAT-SEN UNIVERSITY CANCER CENTRE ( Site 6003)
Guangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital of Guangzhou Medical University-Urology ( Site 6036)
Guangzhou, Guangdong, 510120, China
-
The First Affiliated Hospital of Nanchang University ( Site 6019)
Nanchang, Jiangxi, 330006, China
-
The First Affiliated Hospital of Wenzhou Medical University-Urology Surgery ( Site 6021)
Wenzhou, Zhejiang, 325000, China
-
The First Affiliated Hospital of Xi'an Jiaotong University ( Site 6014)
Xi'an, Shaanxi, 710061, China
-
The First Affiliated Hospital, Zhejiang University ( Site 6024)
Hangzhou, Zhejiang, 310003, China
-
The First Hospital of Jiaxing ( Site 6033)
Jiaxing, Zhejiang, 314001, China
-
The Second Affiliated Hospital of Soochow University-Urology ( Site 6025)
Suzhou, Jiangsu, 215004, China
-
The Second Hospital of Tianjin Medical University ( Site 6032)
Tianjin, Tianjin Municipality, 300211, China
-
West China Hospital Sichuan University-Urology Surgery ( Site 6016)
Chengdu, Sichuan, 610041, China
-
Wuhan Union Hospital ( Site 6002)
Wuhan, Hubei, 430022, China
Conditions
Explore the condition pages connected to this study.